Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing
Running, not enrolling · Not applicable · Has a placebo group
Conditions studied: Opioid-Related Disorders, Buprenorphine, Social Stigma, Rural Health Services
In brief
Buprenorphine is an evidence-based treatment for opioid use disorder that also has strong potential to reduce HIV transmission in people who use drugs. Rural health care professionals are eligible and critically needed to provide these medications, but stigma currently limits provider willingness to prescribe buprenorphine, especially in regions where mortality and HIV transmission secondary to opioid use are high. In this developmental trial, the investigators will adapt, refine, and test the feasibility of a prototype brief stigma-reduction training intervention aimed at increasing buprenorphine prescribing in the rural primary care setting.
Key facts
- Study ID
- NCT05505227
- Run by
- Ohio University
- People needed
- 400
- Starts
- 2022-09-01
- Expected to finish
- 2025-06-30
- Last updated by the study team
- 2025-05-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- physician, nurse practitioner, or physician assistant
- eligible to prescribe buprenorphine under federal law
- currently practices in primary care setting
- currently practices in rural-designated county
- at least 18 years of age
You may not qualify if…
- currently prescribing buprenorphine at full capacity
Where it is running
- Berkeley Franz — Athens, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.